Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Scleroderma: early-phase trial registry
11 of 24 indexed Scleroderma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 11 currently recruiting · #686 of 28,707 conditions by registered trial count
Scleroderma: 24 US clinical trials tracked, 11 recruiting.
Scleroderma is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 4 of these trials.
Enrollment posture brief
Registry condition scleroderma
OPEN 11 | RECR 46% | LATE 3 | EARLY 9 | RANK #686 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Glaucoma Open-Angle (46% recruiting · 24 trials)
Scleroderma lists 11 open slots (46% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Scleroderma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Scleroderma is recruiting above its size-band peers.
11 of 24 indexed trials (45.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Scleroderma research.
Johns Hopkins University accounts for 4 of 24 trials (16.7%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Scleroderma trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 24 trials that report a genuine target (sentinel values excluded). 15 of those (62.5%) plan for fewer than 100 participants.
-
Scleroderma splits between interventional and observational designs.
15 interventional and 9 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Duke University
NCT03276923
Rheumatology Diet Study
University of Central Florida
NCT06339957
Platform Clinical Study for Conquering Scleroderma
Scleroderma Research Foundation
NCT06195072
Scleroderma Registry & Repository at the Hospital for Special Surgery
Hospital for Special Surgery, New York
NCT01656447
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
TScan Therapeutics
NCT06587828
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Artiva Biotherapeutics
NCT06991114
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Zura Bio
NCT06843239
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
University of Michigan
NCT06880627
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Johns Hopkins University
NCT04797286
TENS in Scleroderma
University of Michigan
NCT06646913
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
NCT06328777
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
AstraZeneca
NCT05925803
MRI for Screening and Monitoring Scleroderma ILD
University of Kansas Medical Center
NCT05204355
Scleroderma Registry
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00074568
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
George Washington University
NCT02887495
Novel Screening Strategies for Scleroderma PAH
University of Michigan
NCT01959815
Psychological Treatments for Scleroderma
Johns Hopkins University
NCT00007267
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
MediQuest Therapeutics
NCT00419419
Calcinosis in a Single-Center Scleroderma Population
Rutgers, The State University of New Jersey
NCT02062125
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Johns Hopkins University
NCT02165111
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
MedImmune
NCT00930683
Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma
Johns Hopkins University
NCT03294616
RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach
University of Michigan
NCT06999226
The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma
University of Texas Southwestern Medical Center
NCT04523506
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Scleroderma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Scleroderma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Scleroderma page
24 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Scleroderma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Scleroderma trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Scleroderma condition card totals 24 registered trials; most-linked intervention Placebo; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.